Intestinal Microecological Changes and Therapeutics in Inflammatory Bowel Disease

Bo LI; Yang SUN; Yinglei MIAO

doi:10.12259/j.issn.2095-610X.S20240401

Volume 45 Issue 4

Apr. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(4): 1-8

Bo LI, Yang SUN, Yinglei MIAO. Intestinal Microecological Changes and Therapeutics in Inflammatory Bowel Disease[J]. Journal of Kunming Medical University, 2024, 45(4): 1-8. doi: 10.12259/j.issn.2095-610X.S20240401

Citation:

Bo LI, Yang SUN, Yinglei MIAO. Intestinal Microecological Changes and Therapeutics in Inflammatory Bowel Disease[J]. Journal of Kunming Medical University, 2024, 45(4): 1-8. doi: 10.12259/j.issn.2095-610X.S20240401

Citation:

PDF( 2741 KB)

Intestinal Microecological Changes and Therapeutics in Inflammatory Bowel Disease

doi: 10.12259/j.issn.2095-610X.S20240401

Dept. of Gastroenterology，The 1st Affiliated Hospital of Kunming Medical University/Yunnan Institute of Digestive Disease/Yunnan Clinical Research Center for Digestive Diseases，Kunming Yunnan 650032，China

More Information

Corresponding author: 缪应雷，昆明医科大学第一附属医院主任医师，博士生导师，博士。国家百千万人才工程人选、国家有突出贡献中青年专家、国务院政府特殊津贴、云岭学者、云南省“名医”、云南省医学会消化病学分会-主任委员、国家临床重点专科负责人。主持国家自然科学基金6项（其中重点项目1项），获云南省政府颁发的省级科技进步一等奖2项，三等奖6项。以第一作者或通讯作者发表SCI论文47篇，其中以通讯作者在《Gastroenterology》（IF= 33.883）发表论著2篇、《Cell Host & Microbe》（IF=31.316）发表论著1篇。
Received Date: 2024-04-10
Available Online: 2024-04-21
Publish Date: 2024-04-29

Abstract

Abstract

Inflammatory bowel disease （IBD） is a chronic condition characterised by recurrent inflammation of the intestines. Although the specific causes is not fully understood, it is generally believed to be caused by a combination of genetic factors, immune system abnormalities, environmental factors, and imbalances in the gut microbiota. The interaction of these factors may disrupt the intestinal environment, affecting the host's immune system, and ultimately triggering intestinal inflammation. This review discusses changes in the gut microbiota of IBD patients and explores corresponding treatment strategies.
- Inflammatory bowel disease,
- Intestinal microecological,
- Intestinal flora

FullText(HTML)

References(51)

References

[1]	Mak W Y,Zhao M,Ng S C,et al. The epidemiology of inflammatory bowel disease: East meets west[J]. Journal of Gastroenterology and Hepatology,2020,35(3):380-389. doi: 10.1111/jgh.14872
[2]	包云丽,汪哲,唐海茹,等. 1990-2019年中国炎症性肠病疾病负担及变化趋势分析[J]. 中国全科医学,2023,26(36):4581-4586.
[3]	Xu L,He B,Sun Y,et al. Incidence of inflammatory bowel disease in urban China: A nationwide population-based study[J]. Clinical Gastroenterology and Hepatology,2023,21(13): 3379-3386. e29.
[4]	Ng S C,Shi H Y,Hamidi N,et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies[J]. The Lancet,2017,390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0
[5]	Nakase H,Sato N,Mizuno N,et al. The influence of cytokines on the complex pathology of ulcerative colitis[J]. Autoimmunity Reviews,2022,21(3):103017. doi: 10.1016/j.autrev.2021.103017
[6]	Caparr ó s E,Wiest R,Scharl M,et al. Dysbiotic microbiota interactions in Crohn’ s disease[J]. Gut Microbes,2021,13(1):1949096. doi: 10.1080/19490976.2021.1949096
[7]	Lee M,Chang E B. Inflammatory bowel diseases (IBD) and the microbiome—Searching the crime scene for clues[J]. Gastroenterology,2021,160(2):524-537. doi: 10.1053/j.gastro.2020.09.056
[8]	Hu Y,Chen Z,Xu C,et al. Disturbances of the gut microbiota and microbiota-derived metabolites in inflammatory bowel disease[J]. Nutrients,2022,14(23):5140. doi: 10.3390/nu14235140
[9]	Schirmer M,Garner A,Vlamakis H,et al. Microbial genes and pathways in inflammatory bowel disease[J]. Nature Reviews Microbiology,2019,17(8):497-511. doi: 10.1038/s41579-019-0213-6
[10]	Kennedy J M,De Silva A,Walton G E,et al. A review on the use of prebiotics in ulcerative colitis[J]. Trends Microbiol,2023,Published online .
[11]	Li W,Sun Y,Dai L,et al. Ecological and network analyses identify four microbial species with potential significance for the diagnosis/treatment of ulcerative colitis (UC)[J]. BMC Microbiology,2021,21(1):138. doi: 10.1186/s12866-021-02201-6
[12]	Pittayanon R,Lau J T,Leontiadis G I,et al. Differences in gut microbiota in patients with vs without inflammatory bowel diseases: A systematic review[J]. Gastroenterology,2020,158(4): 930-946. e1.
[13]	Waters J L,Ley R E. The human gut bacteria Christensenellaceae are widespread,heritable,and associated with health[J]. BMC Biology,2019,17(1):83. doi: 10.1186/s12915-019-0699-4
[14]	Hu W,Gao W,Liu Z,et al. Biodiversity and physiological characteristics of novel Faecalibacterium prausnitzii strains isolated from human feces[J]. Microorganisms,2022,10(2):297. doi: 10.3390/microorganisms10020297
[15]	Wang X,Ni J,You Y,et al. SNX10‐mediated LPS sensing causes intestinal barrier dysfunction via a caspase‐5‐dependent signaling cascade[J]. The EMBO Journal,2021,40(24):e108080. doi: 10.15252/embj.2021108080
[16]	Duerkop B A,Kleiner M,Paez-Espino D,et al. Murine colitis reveals a disease-associated bacteriophage community[J]. Nature Microbiology,2018,3(9):1023-1031. doi: 10.1038/s41564-018-0210-y
[17]	Zuo T,Lu X J,Zhang Y,et al. Gut mucosal virome alterations in ulcerative colitis[J]. Gut,2019,68(7):1169-1179. doi: 10.1136/gutjnl-2018-318131
[18]	Cao Z,Fan D,Sun Y,et al. The gut ileal mucosal virome is disturbed in patients with Crohn’ s disease and exacerbates intestinal inflammation in mice[J]. Nature Communications,2024,15(1):1638. doi: 10.1038/s41467-024-45794-y
[19]	Clooney A G,Sutton T D S,Shkoporov A N,et al. Whole-virome analysis sheds light on viral dark matter in inflammatory bowel disease[J]. Cell Host & Microbe,2019,26(6): 764-778. e5.
[20]	Ventin-Holmberg R,Eberl A,Saqib S,et al. Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease[J]. Journal of Crohn’ s and Colitis,2021,15(6):1019-1031. doi: 10.1093/ecco-jcc/jjaa252
[21]	Limon J J,Tang J,Li D,et al. Malassezia is associated with Crohn’ s disease and exacerbates colitis in mouse models[J]. Cell Host & Microbe,2019,25(3): 377-388. e6.
[22]	Rahabi M,Jacquemin G,Prat M,et al. Divergent roles for macrophage C-type lectin receptors,Dectin-1 and mannose receptors,in the intestinal inflammatory response[J]. Cell Reports,2020,30(13): 4386-4398. e5.
[23]	Torres J,Bonovas S,Doherty G,et al. ECCO guidelines on therapeutics in Crohn’ s disease: Medical treatment[J]. Journal of Crohn’ s & colitis,2020,14(1):4-22.
[24]	中华医学会消化病学分会炎症性肠病学组,中国炎症性肠病诊疗质量控制评估中心. 中国溃疡性结肠炎诊治指南(2023年·西安)[J]. 中华炎性肠病杂志(中英文),2024,8(1):33-58.
[25]	中华医学会消化病学分会炎症性肠病学组,中国炎症性肠病诊疗质量控制评估中心. 中国克罗恩病诊治指南(2023年·广州)[J]. 中华炎性肠病杂志(中英文),2024,8(1):2-32.
[26]	Peters V,Bolte L,Schuttert E M,et al. Western and carnivorous dietary patterns are associated with greater likelihood of IBD development in a large prospective population-based cohort[J]. J Crohns Colitis,2022,16(6):931-939. doi: 10.1093/ecco-jcc/jjab219
[27]	Adolph T E,Meyer M,Schwärzler J,et al. The metabolic nature of inflammatory bowel diseases[J]. Nat Rev Gastroenterol Hepatol,2022,19(12):753-767. doi: 10.1038/s41575-022-00658-y
[28]	Narula N,Wong E C L,Dehghan M,et al. Association of ultra-processed food intake with risk of inflammatory bowel disease: Prospective cohort study[J]. BMJ,2021,374:n1554.
[29]	Fritsch J,Garces L,Quintero M A,et al. Low-fat,high-fiber diet reduces markers of inflammation and dysbiosis and improves quality of life in patients with ulcerative colitis[J]. Clinical Gastroenterology and Hepatology,2021,19(6): 1189-1199. e30.
[30]	Wang S,Martins R,Sullivan M C,et al. Diet-induced remission in chronic enteropathy is associated with altered microbial community structure and synthesis of secondary bile acids[J]. Microbiome,2019,7(1):126. doi: 10.1186/s40168-019-0740-4
[31]	Jakubczyk D,Leszczy ń ska K,G ó rska S. The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD)-A critical review[J]. Nutrients,2020,12(7):1973. doi: 10.3390/nu12071973
[32]	Sun M,Liu Y,Song Y,et al. The ameliorative effect of Lactobacillus plantarum-12 on DSS-induced murine colitis[J]. Food & Function,2020,11(6):5205-5222.
[33]	Yao S,Zhao Z,Wang W,et al. Bifidobacterium longum: Protection against inflammatory bowel disease[J]. Journal of Immunology Research,2021,2021:1-11.
[34]	Chen Y,Zhang M,Ren F. A role of exopolysaccharide produced by Streptococcus thermophilus in the intestinal inflammation and mucosal barrier in caco-2 monolayer and dextran sulphate sodium-induced experimental murine colitis[J]. Molecules,2019,24(3):513. doi: 10.3390/molecules24030513
[35]	Kang M,Choi H J,Yun B,et al. Bacillus amyloliquefaciens SCGB1 alleviates dextran sulfate sodium-induced colitis in mice through immune regulation[J]. Journal of Medicinal Food,2021,24(7):709-719. doi: 10.1089/jmf.2021.K.0044
[36]	Choi E J,Lee H J,Kim W J,et al. Enterococcus faecalis EF-2001 protects DNBS-induced inflammatory bowel disease in mice model[J]. PLoS One,2019,14(2):e0210854. doi: 10.1371/journal.pone.0210854
[37]	Tursi A,Brandimarte G,Papa A,et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: A double-blind,randomized,placebo-controlled study[J]. American Journal of Gastroenterology,2010,105(10):2218-2227. doi: 10.1038/ajg.2010.218
[38]	Li S C,Hsu W F,Chang J S,et al. Combination of Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis shows a stronger anti-inflammatory effect than individual strains in HT-29 cells[J]. Nutrients,2019,11(5):969. doi: 10.3390/nu11050969
[39]	Dore M P,Rocchi C,Longo N P,et al. Effect of probiotic use on adverse events in adult patients with inflammatory bowel disease: A retrospective cohort study[J]. Probiotics and Antimicrobial Proteins,2020,12(1):152-159. doi: 10.1007/s12602-019-9517-0
[40]	Gibson G R,Hutkins R,Sanders M E,et al. Expert consensus document: The international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics[J]. Nature Reviews Gastroenterology & Hepatology,2017,14(8):491-502.
[41]	Wilson B,Eyice Ö,Koumoutsos I,et al. Prebiotic galactooligosaccharide supplementation in adults with ulcerative colitis: Exploring the impact on peripheral blood gene expression,Gut Microbiota,and Clinical Symptoms[J]. Nutrients,2021,13(10):3598. doi: 10.3390/nu13103598
[42]	Valcheva R,Koleva P,Mart í nez I,et al. Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels[J]. Gut Microbes,2019,10(3):334-357. doi: 10.1080/19490976.2018.1526583
[43]	Ikegami S,Nakamura M,Honda T,et al. Efficacy of 1-kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised,double-blind,placebo-controlled pilot study[J]. Alimentary Pharmacology & Therapeutics,2023,57(11):1249-1257.
[44]	Xue Z,Li R,Liu J,et al. Preventive and synbiotic effects of the soluble dietary fiber obtained from lentinula edodes byproducts and Lactobacillus plantarum LP90 against dextran sulfate sodium-induced colitis in mice[J]. Journal of the Science of Food and Agriculture,2023,103(2):616-626. doi: 10.1002/jsfa.12173
[45]	Amiriani T,Rajabli N,Faghani M,et al. Effect of Lactocare^® synbiotic on disease severity in ulcerative colitis: A randomized placebo-controlled double-blind clinical trial[J]. Middle East Journal of Digestive Diseases,2019,12(1):27-33. doi: 10.15171/mejdd.2020.160
[46]	Costello S P,Hughes P A,Waters O,et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: A randomized clinical trial[J]. JAMA,2019,321(2):156. doi: 10.1001/jama.2018.20046
[47]	Haifer C,Paramsothy S,Kaakoush N O,et al. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): A randomised,double-blind,placebo-controlled trial[J]. Lancet Gastroenterol Hepatol,2022,7(2):141-151. doi: 10.1016/S2468-1253(21)00400-3
[48]	Boicean A,Birlutiu V,Ichim C,et al. Fecal microbiota transplantation in inflammatory bowel disease[J]. Biomedicines,2023,11(4):1016. doi: 10.3390/biomedicines11041016
[49]	Xu Z,Dong X,Yang K,et al. Association of adherent-invasive Escherichia coli with severe gut mucosal dysbiosis in Hong Kong Chinese population with Crohn’ s disease[J]. Gut Microbes,2021,13(1):1994833. doi: 10.1080/19490976.2021.1994833
[50]	Galtier M,De Sordi L,Sivignon A,et al. Bacteriophages targeting adherent invasive Escherichia coli strains as a promising new treatment for Crohn’ s disease[J]. Journal of Crohn’ s and Colitis,2017,11(7):jjw224.
[51]	Federici S,Kredo-Russo S,Valdés-Mas R,et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation[J]. Cell,2022,185(16): 2879-2898. e24.

Relative Articles(20)

Relative Articles

[1]	Zhangqin LI, Qi HUANG, Yinglei MIAO. Research Progress on Paradoxical Extraintestinal Manifestations of Biologics in the Treatment of Inflammatory Bowel Disease. Journal of Kunming Medical University, 2024, 45(2): 160-165. doi: 10.12259/j.issn.2095-610X.S20240223
[2]	Junjie NIU, Wenjuan JI, Zhuaizhuai YU. Correlation between Gut Microbiota，Serum ET，PCT Levels with the Severity and Prognosis of Sepsis. Journal of Kunming Medical University, 2024, 45(4): 140-145. doi: 10.12259/j.issn.2095-610X.S20240420
[3]	Yuanyuan LI, Yaxian SONG, Yushan XU, Xiaofu ZENG, Hui YUAN, Zhao XU, Yan JIANG. The Association of Intestinal Flora Metabolite TMAO with Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2024, 45(2): 77-84. doi: 10.12259/j.issn.2095-610X.S20240210
[4]	Chun LI, Qiong ZHOU, Cong MEI, Jie jie HUANG, Yi peng WANG, Song lan ZHOU, Qian ZHENG, Zhe TANG. Effect of Bifidobacterium trisporus on Intestinal Microbiota in the Mouse Model of Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2023, 44(10): 77-82. doi: 10.12259/j.issn.2095-610X.S20231022
[5]	Lin XU, Kaicheng GAO, Jie JIA, Yuyang LI, Huawei WANG, Yiqun KUANG, Yu ZHAO. Effect of Shen-ling-bai-zhu-san on Methamphetamine-Induced Gut Microbiota Change in Mice. Journal of Kunming Medical University, 2023, 44(8): 37-43. doi: 10.12259/j.issn.2095-610X.S20230829
[6]	Caihong LIANG, Mingyao MENG, Xinxin LI, Jingjing XIONG, Meng LI, Mei LIU, Zongliu HOU, Yongkun HUANG. Effect of Intestinal Flora Metabolites Deoxycholic Acid on the Proliferation and Cell Cycle of Human Umbilical Cord Mesenchymal Stem Cells. Journal of Kunming Medical University, 2023, 44(4): 23-30. doi: 10.12259/j.issn.2095-610X.S20230402
[7]	Shaoyou DENG, Yulan ZHAO, Peijin WANG, Rong LI, Jintao LI, Hong ZHENG. Effects of Osteoking Combined with Antibiotic Cocktail on Insulin Resistance and Gut Flora in db/db Mice. Journal of Kunming Medical University, 2023, 44(5): 12-18. doi: 10.12259/j.issn.2095-610X.S20230530
[8]	Dan LI, Xulian WAN, Lvyu LI, Yu YUN, Guangyun LUO, Weibing LIU, Gongfu LIN, Ning LI, Yongkun LI, Weigang DUAN. Intestinal Flora in Uricase-Deficient Rats. Journal of Kunming Medical University, 2023, 44(2): 27-32. doi: 10.12259/j.issn.2095-610X.S20230205
[9]	Lu LI, Yunfen TIAN. Research Progress on Intestinal Microflora and Non-alcoholic Fatty Liver Disease in Children. Journal of Kunming Medical University, 2023, 44(7): 148-155. doi: 10.12259/j.issn.2095-610X.S20230708
[10]	Shunhang YANG, Jiongming LI, Jianhe LIU, Guang WANG, Pei LI. Progress in Pathogenesis and Treatment of Enteric Hyperoxaluria. Journal of Kunming Medical University, 2022, 43(7): 152-155. doi: 10.12259/j.issn.2095-610X.S20220734
[11]	Yanqin RUAN, Maojuan LI, Limei HE, Ying SONG, Qiaoyun HUANG, Ying CHEN, Chang LIU. Screening of Special Abnormal Module Items in PRO Scale for Patients with Inflammatory Bowel Disease.. Journal of Kunming Medical University, 2022, 43(3): 37-43. doi: 10.12259/j.issn.2095-610X.S20220310
[12]	Rong LIU, Yang SUN, Fameng LUO, Dezhi TAO, Haiyan ZHANG. Correlation between the Acceptance of Illness and Quality of Life in Patients with Inflammatory Bowel Disease. Journal of Kunming Medical University, 2022, 43(5): 173-178. doi: 10.12259/j.issn.2095-610X.S20220507
[13]	Yandong GUO, Rudan HONG, Yanjiao WANG, Teng ZHANG, Yuemei FENG, Nishang ZHANG, Ying QIAN, Zaogai YANG, Fei MI, Jianzhong YIN. Effects of Perindopril on Intestinal Microecology in Obese Rats. Journal of Kunming Medical University, 2022, 43(11): 9-16. doi: 10.12259/j.issn.2095-610X.S20221101
[14]	Sixiang LIU, Yongkun HUANG, Mingying WANG, Hongwei HU, Min MA, Yu LING. Analysis of Intestinal Flora and Therapeutic Intervention in Children with Functional Constipation. Journal of Kunming Medical University, 2022, 43(3): 123-127. doi: 10.12259/j.issn.2095-610X.S20220309
[15]	Hai-long DAI, Nan WANG, Xiao-qing CHEN, Zhen-yi HE, Xiao-lan FENG, Xue-feng GUANG. Characteristics of Intestinal Microflora in Patients with Coronary Heart Disease. Journal of Kunming Medical University, 2020, 41(12): 36-41. doi: 10.12259/j.issn.2095-610X.S20201213
[16]	Tang Juan , Nian Xin . . Journal of Kunming Medical University, 2020, 41(03): 137-143.
[17]	Liang Rui , Chun Yu Wei Xun , Shen Dao , Sun Le , Li Yun Feng . . Journal of Kunming Medical University, 2020, 41(06): 156-161.
[18]	Ping-yan XUE, Yan JIANG, Yu-shan XU, Hui YUAN, Xuan LI, Ya-xian SONG, Hua LIU. Changes of Intestinal Flora in Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2020, 41(11): 62-67. doi: 10.12259/j.issn.2095-610X.S20201120
[19]	Wang Rui Tao , Jia Qing An , Mou Yi Ping , Geng Zhi Min , Liu Chang . The Clinical Evaluation of Danning Tablets on Regulating Gut Flora Displacement to Eliminate Biliary Inflammation and Prevent Gallstone Formation. Journal of Kunming Medical University, 2018, 39(01): 109-112.
[20]	Zhang An Xing , Wu Jing , Sun Yang , Miao Ying Lei . . Journal of Kunming Medical University, 2018, 39(09): 128-132.